Phase 1Completed

Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir

A Phase 1, Open-Label, Single-Sequence Study to Assess the Effect of Multiple Doses of Omeprazole on the Single-Dose Pharmacokinetics of Bemnifosbuvir/Ruzasvir Fixed-Dose Combination in Healthy Adult Participants

Sponsor

Atea Pharmaceuticals, Inc. (Industry)

Enrollment

20 enrolled

Conditions

Healthy Volunteer Study

Interventions

Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting; Treatment B-Omeprazole 20 mg dose administered fasting; Treatment C-Bemnifosbuvir/Ruzasvir FDC administered simultaneously with 20 mg dose of Omeprazole fasting; Treatment D-Bemnifosbuvir/Ruzasvir FDC administered 0.5 hour prior to 20 mg dose of Omeprazole; Treatment E-Omeprazole 40 mg administered fasting; Treatment F-Bemnifosbuvir/Ruzasvir FDC administered 2 hours after 40 mg dose Omeprazole

Ages

adults

Registry

NCT07007806

Full record on ClinicalTrials.gov